Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Advancements in MS include promising therapies like BTK inhibitors and myelin repair, evolving biomarkers, and a focus on cognition, signaling a promising future in precision medicine.

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study, MS treatment ...